{
  "source": "PA-Med-Nec-Afrezza.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2056-11\nProgram Prior Authorization/Medical Necessity\nMedication Afrezza® (insulin human)\nP&T Approval Date 7/2015, 7/2016, 4/2017, 5/2018, 6/2019, 6/2020, 7/2021, 2/2022, 2/2023,\n2/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nAfrezza is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients\nwith diabetes mellitus. Coverage criteria outlined below are for patients unable to self-inject\nshort-acting insulin.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Afrezza* will be approved based on all of the following criteria:\na. One of the following:\n(1) Diagnosis of type 1 diabetes mellitus and used in combination with a basal insulin\nor continuous insulin pump\n-OR-\n(2) Diagnosis of type 2 diabetes mellitus\n-AND-\nb. Patient is unable to self-inject medications (e.g. Humalog, Lantus, Toujeo) due to one of\nthe followingb:\n(1) Physical impairment\n(2) Visual impairment\n(3) Lipohypertrophy\n(4) Documented needle-phobia to the degree that the patient has\npreviously refused any injectable therapy or medical procedure (refer to\nDSM-5 for specific phobia diagnostic criteria2)\n-AND-\nc. FEV1 within the last 60 days is greater than or equal to 70% of expected normal as\ndetermined by the physicianb\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\nd. Afrezza will NOT be approved in patientsb:\n(1) Who smoke cigarettes\n(2) Who recently quit smoking (within the past 6 months)\n(3) With chronic lung disease (e.g. asthma, chronic obstructive pulmonary disease)\nInitial authorization will be issued for 12 months\nB. Reauthorizationb\n1. Afrezza will be approved based on both of the following criteria:\na. Repeat pulmonary function test confirms that patient has NOT experienced a decline of\n20% or more in FEV1\n-AND-\nb. Patient continues to be unable to self-inject short-acting insulin due to one of the\nfollowing:\n(1) Physical impairment\n(2) Visual impairment\n(3) Lipohypertrophy\n(4) Docu",
    "\n20% or more in FEV1\n-AND-\nb. Patient continues to be unable to self-inject short-acting insulin due to one of the\nfollowing:\n(1) Physical impairment\n(2) Visual impairment\n(3) Lipohypertrophy\n(4) Documented needle-phobia to the degree that the patient has\npreviously refused any injectable therapy or medical procedure (refer to\nDSM-5 for specific phobia diagnostic criteria2)\n-AND-\nc. Patient continues to not smoke cigarettes\nReauthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply\nb In Florida, Maine, and Tennessee only, medications prescribed for diabetes may be approved\nbased on both of the following: 1) Provider attests use of this product is medically necessary for\nthe treatment of diabetes; and- 2) If applicable, clinical characteristics exist that preclude the use\nof the covered preferred alternative(s) and use of the covered preferred alternative(s) could result\nin worsening of patient’s condition or inadequate treatment (document alternatives and clinical\ninformation related to worsening/inadequate treatment).\n*Typically excluded from coverage\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place\n© 2025 UnitedHealthcare Services Inc.\n2\n4. References:\n1. Afrezza [package insert]. Danbury, CT: MannKind Corporation; February 2023.\n2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth\nEdition, Text Revision. Arlington, VA, American Psychiatric Association, 2022.\nProgram Prior Authorization/Medical Necessity – Afrezza\nChange Control\nDate Cha",
    "istical Manual of Mental Disorders, Fifth\nEdition, Text Revision. Arlington, VA, American Psychiatric Association, 2022.\nProgram Prior Authorization/Medical Necessity – Afrezza\nChange Control\nDate Change\n7/2015 New program.\n7/2016 Annual review. Clarified that basal insulin could include continuous\ninsulin pump.\n4/2017 Removal of medical record requirement.\n5/2018 Annual review. Updated references.\n6/2019 Annual review. Updated references.\n6/2020 Annual review. Updated references. Added state mandate language.\n7/2021 Annual review. Updated references.\n2/2022 Added Florida, Maine, and Tennessee mandate language.\n2/2023 Annual review. Updated examples of self-injected medications.\n2/2024 Annual review. Updated references. Updated state mandate language.\n4/2025 Annual review with no changes.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}